Diabetes mellitus is associated with reduced high-density lipoprotein sphingosine-1-phosphate content and impaired high-density lipoprotein cardiac cell protection

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 36, Issue 5, 2016, Pages 817-824

  Brinck, Jonas W ^a,d   Thomas, Aurélien ^b,c   Lauer, Estelle ^b   Jornayvaz, François R ^a   Brulhart Meynet, Marie Claude ^a   Prost, Jean Christophe ^b   Pataky, Zoltan ^a   Löfgren, Patrik ^d   Hoffstedt, Johan ^d   Eriksson, Mats ^d   Pramfalk, Camilla ^e   Morel, Sandrine ^a   Kwak, Brenda R ^a   Van Eck, Miranda ^f   James, Richard W ^a   Frias, Miguel A ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f LEIDEN UNIVERSITY   (Netherlands)

Author keywords

AGE; cardiomyocytes; glycation; HDL; ischemia reperfusion injury; sphingosine 1 phosphate; type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; METHYLGLYOXAL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SPHINGOSINE 1 PHOSPHATE; STAT3 PROTEIN; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; LYSOPHOSPHOLIPID; SCARB1 PROTEIN, MOUSE; SCARB1 PROTEIN, RAT; SCAVENGER RECEPTOR B; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE;

ADULT; ARTICLE; CARDIAC MUSCLE CELL; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; EX VIVO STUDY; FEMALE; GLYCATION; HEART PROTECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; C57BL MOUSE; CASE CONTROL STUDY; CELL CULTURE; COMPLICATION; DEFICIENCY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; GENETIC TRANSFECTION; GENETICS; GENOTYPE; GLYCOSYLATION; ISOLATED HEART; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL REPERFUSION INJURY; NEWBORN; PATHOLOGY; PHENOTYPE; RNA INTERFERENCE; TIME FACTOR; WISTAR RAT;

ANIMALS; ANIMALS, NEWBORN; CASE-CONTROL STUDIES; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DYSLIPIDEMIAS; GENOTYPE; GLYCOSYLATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ISOLATED HEART PREPARATION; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; OXIDATIVE STRESS; PHENOTYPE; RATS, WISTAR; RNA INTERFERENCE; SCAVENGER RECEPTORS, CLASS B; SPHINGOSINE; TIME FACTORS; TRANSFECTION;

EID: 84960433832     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.115.307049     Document Type: Article

References (41)

1. Grundy SM, Garber A, Goldberg R, Havas S, Holman R, Lamendola C, Howard WJ, Savage P, Sowers J, Vega GL, Prevention conference VI: diabetes and cardiovascular disease: writing group IV: lifestyle and medical management of risk factors. Circulation 2002 105 e153 e158
2. Goldberg IJ, Clinical review 124: Diabetic dyslipidemia: causes and consequences. J Clin Endocrinol Metab 2001 86 965 971. doi: 10.1210/jcem.86.3.7304
3. Chahil TJ, Ginsberg HN, Diabetic dyslipidemia. Endocrinol Metab Clin North Am 2006 35 491 510, vii. doi: 10.1016/j.ecl.2006.06.002
4. Kiuchi K, Nejima J, Takano T, Ohta M, Hashimoto H, Increased serum concentrations of advanced glycation end products: a marker of coronary artery disease activity in type 2 diabetic patients. Heart 2001 85 87 91
5. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J, Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009 302 1993 2000. doi: 10.1001/jama.2009.1619
6. Davidsson P, Hulthe J, Fagerberg B, Camejo G, Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010 30 156 163. doi: 10.1161/ATVBAHA.108.179317
7. Ståhlman M, Fagerberg B, Adiels M, Ekroos K, Chapman JM, Kontush A, Borén J, Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles. Biochim Biophys Acta 2013 1831 1609 1617. doi: 10.1016/j.bbalip.2013.07.009
8. Gordon SM, Davidson WS, Urbina EM, Dolan LM, Heink A, Zang H, Lu LJ, Shah AS, The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth. Diabetes 2013 62 2958 2967. doi: 10.2337/db12-1753
9. Morgantini C, Natali A, Boldrini B, Imaizumi S, Navab M, Fogelman AM, Ferrannini E, Reddy ST, Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 2011 60 2617 2623. doi: 10.2337/db11-0378
10. Singal PK, Iliskovic N, Doxorubicin-induced cardiomyopathy. N Engl J Med 1998 339 900 905. doi: 10.1056/NEJM199809243391307
11. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET, Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med 2012 18 1639 1642. doi: 10.1038/nm.2919
12. Frias MA, Lang U, Gerber-Wicht C, James RW, Native and reconstituted HDL protect cardiomyocytes from doxorubicin-induced apoptosis. Cardiovasc Res 2010 85 118 126. doi: 10.1093/cvr/cvp289
13. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, Raffai R, High-density lipoprotein determines adult mouse cardiomyocyte fate after hypoxia-reoxygenation through lipoprotein-Associated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 2010 298 H1022 H1028. doi: 10.1152/ajpheart.00902.2009
14. Frias MA, Pedretti S, Hacking D, Somers S, Lacerda L, Opie LH, James RW, Lecour S, HDL protects against ischemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis 2013 228 110 116. doi: 10.1016/j.atherosclerosis.2013.02.003
15. Frias MA, Lecour S, James RW, Pedretti S, High density lipoprotein/sphingosine-1-phosphate-induced cardioprotection: role of STAT3 as part of the SAFE pathway. JAKSTAT 2012 1 92 100. doi: 10.4161/jkst.19754
16. Pupa SM, Giuffré S, Castiglioni F, Bertola L, Cantú M, Bongarzone I, Baldassari P, Mortarini R, Argraves WS, Anichini A, Menard S, Tagliabue E, Regulation of breast cancer response to chemotherapy by fibulin-1. Cancer Res 2007 67 4271 4277. doi: 10.1158/0008-5472.CAN-06-4162
17. Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnström J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, Dahlbäck B, Endothelium-protective sphingosine-1-phosphate provided by HDL-Associated apolipoprotein M. Proc Natl Acad Sci U S A 2011 108 9613 9618. doi: 10.1073/pnas.1103187108
18. Kontush A, Therond P, Zerrad A, Couturier M, Négre-Salvayre A, de Souza JA, Chantepie S, Chapman MJ, Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007 27 1843 1849. doi: 10.1161/ATVBAHA.107.145672
19. Theilmeier G, Schmidt C, Herrmann J, High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006 114 1403 1409. doi: 10.1161/CIRCULATIONAHA.105.607135
20. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S, Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 2012 26 227 237. doi: 10.1007/s10557-012-6376-2
21. Brown BE, Nobecourt E, Zeng J, Jenkins AJ, Rye KA, Davies MJ, Apolipoprotein A-I glycation by glucose and reactive aldehydes alters phospholipid affinity but not cholesterol export from lipid-laden macrophages. PLoS One 2013 8 e65430. doi: 10.1371/journal.pone.0065430
22. Nobecourt E, Davies MJ, Brown BE, Curtiss LK, Bonnet DJ, Charlton F, Januszewski AS, Jenkins AJ, Barter PJ, Rye KA, The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase. Diabetologia 2007 50 643 653. doi: 10.1007/s00125-006-0574-z
23. Kurosaki Y, Tsukushi T, Munekata S, Akahoshi T, Moriya T, Ogawa Z, Semiquantitative analysis of apolipoprotein A-I modified by advanced glycation end products in diabetes mellitus. J Clin Lab Anal 2013 27 231 236. doi: 10.1002/jcla.21591
24. Godfrey L, Yamada-Fowler N, Smith J, Thornalley PJ, Rabbani N, Arginine-directed glycation and decreased HDL plasma concentration and functionality. Nutr Diabetes 2014 4 e134. doi: 10.1038/nutd.2014.31
25. Galvani S, Sanson M, Blaho VA, Swendeman SL, Obinata H, Conger H, Dahlbäck B, Kono M, Proia RL, Smith JD, Hla T, HDL-bound sphingosine 1-phosphate acts as a biased agonist for the endothelial cell receptor S1P1 to limit vascular inflammation. Sci Signal 2015 8 ra79. doi: 10.1126/scisignal.aaa2581
26. Blaho VA, Galvani S, Engelbrecht E, Liu C, Swendeman SL, Kono M, Proia RL, Steinman L, Han MH, Hla T, HDL-bound sphingosine-1-phosphate restrains lymphopoiesis and neuroinflammation. Nature 2015 523 342 346. doi: 10.1038/nature14462
27. Denimal D, Pais de Barros JP, Petit JM, Bouillet B, Vergès B, Duvillard L, Significant abnormalities of the HDL phosphosphingolipidome in type 1 diabetes despite normal HDL cholesterol concentration. Atherosclerosis 2015 241 752 760. doi: 10.1016/j.atherosclerosis.2015.06.040
28. Cervin C, Axler O, Holmkvist J, Almgren P, Rantala E, Tuomi T, Groop L, Dahlbäck B, Karlsson E, An investigation of serum concentration of apoM as a potential MODY3 marker using a novel ELISA. J Intern Med 2010 267 316 321. doi: 10.1111/j.1365-2796.2009.02145.x
29. Skupien J, Kepka G, Gorczynska-Kosiorz S, Gebska A, Klupa T, Wanic K, Nowak N, Borowiec M, Sieradzki J, Malecki MT, Evaluation of Apolipoprotein M Serum Concentration as a Biomarker of HNF-1alpha MODY. Rev Diabet Stud 2007 4 231 235. doi: 10.1900/RDS.2007.4.231
30. Out R, Hoekstra M, Spijkers JA, Kruijt JK, van Eck M, Bos IS, Twisk J, Van Berkel TJ, Scavenger receptor class B type I is solely responsible for the selective uptake of cholesteryl esters from HDL by the liver and the adrenals in mice. J Lipid Res 2004 45 2088 2095. doi: 10.1194/jlr.M400191-JLR200
31. Sattler K, Levkau B, Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009 82 201 211. doi: 10.1093/cvr/cvp070
32. Xu N, Dahlbäck B, A novel human apolipoprotein (apoM). J Biol Chem 1999 274 31286 31290
33. Gåfvels M, Bengtson P, A fast semi-quantitative LC-MS method for measurement of intact apolipoprotein A-I reveals novel proteoforms in serum. Clin Chim Acta 2015 442 87 95. doi: 10.1016/j.cca.2015.01.011
34. Tong X, Lv P, Mathew AV, Liu D, Niu C, Wang Y, Ji L, Li J, Fu Z, Pan B, Pennathur S, Zheng L, Huang Y, The compensatory enrichment of sphingosine-1-phosphate harbored on glycated high-density lipoprotein restores endothelial protective function in type 2 diabetes mellitus. Cardiovasc Diabetol 2014 13 82. doi: 10.1186/1475-2840-13-82
35. Jing XD, Wei XM, Deng SB, Du JL, Liu YJ, She Q, The relationship between the high-density lipoprotein (HDL)-Associated sphingosine-1-phosphate (S1P) and coronary in-stent restenosis. Clin Chim Acta 2015 446 248 252. doi: 10.1016/j.cca.2015.04.038
36. Kontush A, Chapman MJ, Why is HDL functionally deficient in type 2 diabetes? Curr Diab Rep 2008 8 51 59
37. Sevvana M, Ahnström J, Egerer-Sieber C, Lange HA, Dahlbäck B, Muller YA, Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M. J Mol Biol 2009 393 920 936. doi: 10.1016/j.jmb.2009.08.071
38. Ferretti G, Bacchetti T, Marchionni C, Caldarelli L, Curatola G, Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 2001 38 163 169
39. Barter PJ, Caulfield M, Eriksson M, ILLUMINATE Investigators Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007 357 2109 2122. doi: 10.1056/NEJMoa0706628
40. Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J, HPS2-THRIVE Collaborative Group Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014 371 203 212. doi: 10.1056/NEJMoa1300955
41. Kurano M, Hara M, Tsuneyama K, Sakoda H, Shimizu T, Tsukamoto K, Ikeda H, Yatomi Y, Induction of insulin secretion by apolipoprotein M, a carrier for sphingosine 1-phosphate. Biochim Biophys Acta 2014 1841 1217 1226. doi: 10.1016/j.bbalip.2014.05.002